• Qiagen entered automation partnership with Inpeco to build track-based, end-to-end automation for QuantiFERON latent TB testing in high-throughput laboratories.
• Workflow, targeted for late 2027 launch, integrates QuantiFERON testing with Diasorin LIAISON detection systems, aiming to remove routine manual intervention from tube handling and incubation through detection.
• Design includes dedicated QuantiFERON aliquoting system, intelligent incubation system integrated into automation track, aiming to cut hands-on time by up to 80% while enabling continuous processing.
• Separate AI-enabled risk stratification tool for TB progression, also targeted for late 2027, is being developed to analyze quantitative QuantiFERON results using about 13 million de-identified patient records.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 202605070600BIZWIRE_USPR_____20260507_BW961570) on May 07, 2026, and is solely responsible for the information contained therein.